PRL型垂体瘤患者血清miRNA表达谱的检测及初步筛选分析
|
摘要
目的检测及初步筛选分析PRL型垂体瘤患者血清miRNA表达谱。方法采集20例PRL型垂体瘤患者和20例健康志愿者血清,通过RNA提取技术、miRNA TLDA芯片技术检测血清miRNA、采用软件Data AssistTMSoftware进行数据分析和处理,筛选出差异性表达的miRNA。结果以差异表达量大于2倍,芯片检测的相对定量平均CT值小于40为标准,初步筛选出PRL型垂体瘤患者血清miRNA表达上调的有3个,表达下调的有25个,共计28个。结论 PRL型垂体瘤患者和健康志愿者血清miRNA具有内源表达的差异性,可以为进一步验证特异性血清miRNA的表达,探索药物临床疗效机制研究提供理论和实验依据。
Objective To detect and preliminarily screen and analyze serum miRNA expression profile in the patients of PRL- type hypophysoma. Methods The serum was collected from 20 patients of PRL- type hypophysoma and 20 healthy volunteers. RNA extract technology and miRNA TLDA chip technology were used to detect serum miRNA. The Data Assist TM Software was adopted for the analysis and management of data and for screening the differences of miRNA expressions. Results By taking the expression difference( by more than 2 times) and the mean CT value( > 40) of the relative quantification detected by chip as the criteria,it was preliminarily screened that 3 miRNA expressions were up- regulated and 25 were down-regulated in the patients of PRL- type hypophysoma,totally 28 expressions were involved. Conclusion The endogenous expressions of serum miRNA were different between the patients of PRL- type hypophysoma and healthy volunteers so that the specificity of serum miRNA expressions can be further verified and the theoretic and experimental evidences be provided for the exploration of clinical efficacy mechanism of medicines.
Objective To detect and preliminarily screen and analyze serum miRNA expression profile in the patients of PRL- type hypophysoma. Methods The serum was collected from 20 patients of PRL- type hypophysoma and 20 healthy volunteers. RNA extract technology and miRNA TLDA chip technology were used to detect serum miRNA. The Data Assist TM Software was adopted for the analysis and management of data and for screening the differences of miRNA expressions. Results By taking the expression difference( by more than 2 times) and the mean CT value( > 40) of the relative quantification detected by chip as the criteria,it was preliminarily screened that 3 miRNA expressions were up- regulated and 25 were down-regulated in the patients of PRL- type hypophysoma,totally 28 expressions were involved. Conclusion The endogenous expressions of serum miRNA were different between the patients of PRL- type hypophysoma and healthy volunteers so that the specificity of serum miRNA expressions can be further verified and the theoretic and experimental evidences be provided for the exploration of clinical efficacy mechanism of medicines.
引文
[1]Avraham R,Yarden Y.Regulation of signalling by micro RNAs[J].Biochem Soc Trans,2012,40(1):26-30.
[2]Gommans WM,Berezikov E.Controlling miRNA regulation in disease[J].Methods Mol Biol,2012,822(2):1-18.
[3]Zhou L,Zhao YP,Liu WJ,et al.Circulating microRNAs in cancer:diagnostic and prognostic significance[J].Expert Rev Anticancer Ther,2012,12(2):283-288.
[4]Sotiopoulou G,Pampalakis G,Lianidou E,et al.Emerging of micro RNAs as molecular switches in the integrated circuit of the cancer cell[J].RNA,2009,15(8):1443-1461.
[5]Lu J,Gerz G,Miska EA,et al.Micro RNA expression profiles classify human cancer[J].Nature,2005(435):834-838.
[6]Malumbres R,Sarosiek KA,Cubedo E,et al.Differentiation stage specific expression of micro RNAs in B lymphocytes and diffuse large B cell lymphomas[J].Blood,2009,113(16):3754-3764.
[7]Mattie MD,Benz C C,Bowers J,et al.Optimized high throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Molecular cancer,2006(5):24.
[8]Akhavantabasi S,Sapmas A,Tuna S,et al.miR-125b Targets ARID3B in Breast Cancer Cells[J].Cell Struct Funct,2012,37(1):27-38.
[9]Han Z,Yang Q,Liu B,et al.MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol[J].Carcinogenesis,2012,33(1):131-139.
[10]Liu H,Zhu L,Liu B,et al.Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer[J].Cancer Lett.2012,316(2):196-203.
[11]Kota J,Chivukula RR,Donnell KA,et al.Therapeutic micro RNA delivery suppresses tumorigenesis in a murine liver cancer model[J].Cell,2009,137(6):1005-1017.
[12]Yamamoto Y,Kosaka N,Tanaka M,et al.MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma[J].Biomarkers,2009,14(7):529-538.
[13]Brase JC,Johannes M,Schlomm T,et al.Circulating miRNAs are correlated with tumor progression in prostate cancer[J].Int J Cancer,2011,128(3):608-616.
[14]Butz H,Liko I,Czirjak S,et al.MicroRNA profile indicates downregulation of the TGF-βpathway in sporadic non-functioning pituitary adenomas.Pituitary,2011,14(2):112-124.
[15]Amaral FC,Torres N,Saggioro F,et al.MicroRNAs differentially expressed in ACTH-secreting pituitary tumors[J].J Clin Endocrinol Metab,2009,94(1):320-323.
[16]Cimmino A,Calin GA,Fabbri M,et al.miR-15 and miR-16 induce apoptosis by targeting BCL2[J].Proc Natl Acad Sci USA,2005,102(39):13944-13949.
[17]梁思泉.垂体腺瘤中miRNA基因的研究[D].天津:天津医科大学,2006:651.
[18]赵浩魏俊吉王任直.miRNA与垂体腺瘤[J].医学研究杂志,2009,3(7):5-8.
[19]Bottoni A,Zatelli MC,Ferracin M,et al.Identification of differentially expressed microRNAs by microarray:a possible role of microRNA genes in pituitary adenomas[J].J Cell Physilo,2007,210(2):370-377.
[20]吴留洋,霍钢,杜安东,等.miRNA在侵袭性垂体腺瘤中表达的初步研究[J].中国神经精神疾病杂志,2011,37(12):752-755.
[2]Gommans WM,Berezikov E.Controlling miRNA regulation in disease[J].Methods Mol Biol,2012,822(2):1-18.
[3]Zhou L,Zhao YP,Liu WJ,et al.Circulating microRNAs in cancer:diagnostic and prognostic significance[J].Expert Rev Anticancer Ther,2012,12(2):283-288.
[4]Sotiopoulou G,Pampalakis G,Lianidou E,et al.Emerging of micro RNAs as molecular switches in the integrated circuit of the cancer cell[J].RNA,2009,15(8):1443-1461.
[5]Lu J,Gerz G,Miska EA,et al.Micro RNA expression profiles classify human cancer[J].Nature,2005(435):834-838.
[6]Malumbres R,Sarosiek KA,Cubedo E,et al.Differentiation stage specific expression of micro RNAs in B lymphocytes and diffuse large B cell lymphomas[J].Blood,2009,113(16):3754-3764.
[7]Mattie MD,Benz C C,Bowers J,et al.Optimized high throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Molecular cancer,2006(5):24.
[8]Akhavantabasi S,Sapmas A,Tuna S,et al.miR-125b Targets ARID3B in Breast Cancer Cells[J].Cell Struct Funct,2012,37(1):27-38.
[9]Han Z,Yang Q,Liu B,et al.MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol[J].Carcinogenesis,2012,33(1):131-139.
[10]Liu H,Zhu L,Liu B,et al.Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer[J].Cancer Lett.2012,316(2):196-203.
[11]Kota J,Chivukula RR,Donnell KA,et al.Therapeutic micro RNA delivery suppresses tumorigenesis in a murine liver cancer model[J].Cell,2009,137(6):1005-1017.
[12]Yamamoto Y,Kosaka N,Tanaka M,et al.MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma[J].Biomarkers,2009,14(7):529-538.
[13]Brase JC,Johannes M,Schlomm T,et al.Circulating miRNAs are correlated with tumor progression in prostate cancer[J].Int J Cancer,2011,128(3):608-616.
[14]Butz H,Liko I,Czirjak S,et al.MicroRNA profile indicates downregulation of the TGF-βpathway in sporadic non-functioning pituitary adenomas.Pituitary,2011,14(2):112-124.
[15]Amaral FC,Torres N,Saggioro F,et al.MicroRNAs differentially expressed in ACTH-secreting pituitary tumors[J].J Clin Endocrinol Metab,2009,94(1):320-323.
[16]Cimmino A,Calin GA,Fabbri M,et al.miR-15 and miR-16 induce apoptosis by targeting BCL2[J].Proc Natl Acad Sci USA,2005,102(39):13944-13949.
[17]梁思泉.垂体腺瘤中miRNA基因的研究[D].天津:天津医科大学,2006:651.
[18]赵浩魏俊吉王任直.miRNA与垂体腺瘤[J].医学研究杂志,2009,3(7):5-8.
[19]Bottoni A,Zatelli MC,Ferracin M,et al.Identification of differentially expressed microRNAs by microarray:a possible role of microRNA genes in pituitary adenomas[J].J Cell Physilo,2007,210(2):370-377.
[20]吴留洋,霍钢,杜安东,等.miRNA在侵袭性垂体腺瘤中表达的初步研究[J].中国神经精神疾病杂志,2011,37(12):752-755.